#United States #Anixa Biosciences #San Jose #Cancer Treatment #Amit Kumar

Anixa Biosciences CEO Updates Shareholders

On January 21, 2025, Anixa Biosciences, Inc. released a letter from their Chairman and CEO, Dr. Amit Kumar, detailing significant progress and promising prospects as a biotechnology leader in cancer treatment. The letter highlights notable achievements from 2024 and ambitious targets for the coming year.

Anixa, publicly traded under NASDAQ: ANIX, has been making headlines with its focus on innovative therapies aimed at meeting the challenges posed by cancer. Dr. Kumar expressed genuine enthusiasm about the company's progress, stating that the previous year was marked by various achievements that underscored their dedication to developing effective cancer therapies and vaccines.

One of the critical points in the report was the judicious financial management exhibited throughout 2024. The company spent just $7 million while maintaining $20 million in cash and investments, ensuring a robust financial standing. This stability provides Anixa the essential leverage required to explore additional advancements in their medical programs seamlessly.

A pivotal highlight came from the Society for Immunotherapy of Cancer (SITC) conference conducted in November 2024. Dr. Kumar shared initial promising data from Anixa’s breast cancer vaccine trial. Under this program, they evaluated three groups:

1. Recurrence Group: Patients who are survivors of triple-negative breast cancer (TNBC) concerned about recurrence after treatment.
2. Prevention Group: Women with certain genetic mutations that increase their likelihood of developing breast cancer.
3. Therapeutic Group: Women whose residual disease remains after standard care, where the vaccine was used in combination with Keytruda (pembrolizumab).

Encouraging trends were observed across all groups, with over 70% of participants demonstrating protocol-defined immune responses. Looking to 2025, plans are already in the works to advance to the Phase 2 trial of the breast cancer vaccine, marking an essential step forward in this innovative treatment’s journey.

Expanding on their success in the breast cancer arena, Dr. Kumar noted plans to develop vaccines for other critical cancers, including prostate, lung, and colon cancers. The collaboration with the National Cancer Institute continues concerning the ovarian cancer vaccine, signaling a determined effort to diversify their therapeutic range. Alongside these advances, Anixa's patent portfolio has also expanded, enhancing their intellectual property rights amid a dynamic medical landscape.

The letter also detailed progress within their CAR-T program, targeting ovarian cancer. The treatment for the second dose cohort has been completed, and the third cohort is now underway. Remarkably, a patient from the first dose cohort was granted FDA authorization for a second dose, showing a positive response 21 months post-treatment, indicating the CAR-T therapy’s potential as a long-term treatment option for ovarian cancer. This innovative treatment distinguishes itself from standard CAR-T therapies as it aims to provide solutions for solid tumors, a significant challenge in current oncological practices.

As we look at 2025, Anixa aims to:

• - Complete the Phase 1 trial of the breast cancer vaccine and share further data at multiple scientific conferences, adulting its Phase 2 trial.
• - Advance the CAR-T clinical trial through additional cohorts and prepare for pre-clinical studies targeting solid tumors beyond ovarian cancer.
• - Continue momentum in vaccine development, with updates slated throughout the year for their new cancer indications.

With their current cash reserves affording over 2.5 years of operational runway, Anixa prides itself on a cash structure devoid of warrants or preferred stock, thereby positioning itself favorably for upcoming challenges and opportunities.

Dr. Kumar’s concluding remarks in the letter emphasized Anixa’s dedication to pioneering transformative therapies against cancer, driving innovation that aligns with patient-centric outcomes. His gratitude to shareholders reiterated the collective purpose in tackling the complexities surrounding cancer research and therapy.

Anixa Biosciences continues to stand at the leading edge of biotechnology, forging paths to a future where more effective treatments become a reality, emphasizing innovation, partnership, and a relentless focus on patient health.

For more information on their mission and ongoing projects, you can visit Anixa Biosciences or follow them on their social media platforms.